Merck KGaA (XSWX:MER) Long-Term Debt: CHF0 Mil (As of Mar. 2026)


XSWX:MER Merck KGaA XSWX:MER
81 GF Score
Price CHF132.80
GF Value CHF125.76
! 9 Warning Signs
View Full Analysis

What is Merck KGaA Long-Term Debt?

Merck KGaA XSWX:MER 81 Long-Term Debt is CHF0 Mil as of Mar. 2026. GuruFocus rates XSWX:MER with a GF Score™ of 81/100 and a GF Value™ of CHF125.76. The stock has 9 warning signs investors should review.

Merck KGaA's Long-Term Debt for the quarter that ended in Mar. 2026 was CHF0 Mil.

Merck KGaA's quarterly Long-Term Debt increased from Sep. 2025 (CHF0 Mil) to Dec. 2025 (CHF9,524 Mil) but then declined from Dec. 2025 (CHF9,524 Mil) to Mar. 2026 (CHF0 Mil).

Merck KGaA's annual Long-Term Debt declined from Dec. 2023 (CHF8,342 Mil) to Dec. 2024 (CHF5,950 Mil) but then increased from Dec. 2024 (CHF5,950 Mil) to Dec. 2025 (CHF9,524 Mil).

Merck KGaA  (XSWX:MER) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Merck KGaA Long-Term Debt Related Terms

Merck KGaA Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Long-Term Debt Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,250.50 8,717.96 8,342.44 5,949.91 9,523.61

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 9,523.61 0.00
XSWX:MER
81GF Score
Merck KGaA XSWX:MER
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of CHF0 Mil mean?
Merck KGaA (XSWX:MER) has a Long-Term Debt of CHF0 Mil as of Mar. 2026.
Is Merck KGaA's Long-Term Debt too high?
Merck KGaA's current Long-Term Debt is CHF0 Mil. Overall, Merck KGaA has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Long-Term Debt compare to ZTS and UTHR?
Merck KGaA's Long-Term Debt of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Merck KGaA's current Long-Term Debt is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Merck KGaA (XSWX:MER) has a current Long-Term Debt of CHF0 Mil. The stock's GF Value™ is CHF125.76, compared to a current price of CHF132.80 — trading 5.6% above its estimated fair value. The current Long-Term Debt is CHF0 Mil. Merck KGaA's overall GF Score™ is 81/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Merck KGaA (XSWX:MER), the current Long-Term Debt is CHF0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (XSWX:MER) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be overvalued. The current stock price of CHF132.80 is trading 5.6% above its estimated GF Value™ of CHF125.76.

Key valuation signals for XSWX:MER:

  • Long-Term Debt: CHF0 Mil
  • GF Value™: CHF125.76 vs. price of CHF132.80 (5.6% above fair value)
  • GF Score™: 81/100 with 9 warning signs

No single metric tells the full story. See the XSWX:MER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
81GF Score

Get the complete analysis for XSWX:MER

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF132.80
Price
CHF125.76
GF Value